Biochemical Pharmacology is an international peer reviewed journal devoted to publishing original research and invited reviews and commentaries on the interaction of chemical compounds with biological systems. Manuscripts describing experiments conducted with chemical mixtures, plant or animal extracts will not be considered for publication unless the chemical structures and precise concentrations of all substances are reported.
While particular emphasis is placed on reporting findings that relate to pharmacodynamics, pharmacokinetics, and metabolism of both small molecules and biologics at the biochemical and molecular levels, submissions in the areas of behavioral and physiological pharmacology and toxicology are considered if they describe studies directed at defining mechanisms of action. All areas related to the field of pharmacology are represented in the journal including, but not limited to, chemotherapy, neuropharmacology, inflammation/immunopharmacology, antimicrobials, behavioral, respiratory, gastrointestinal, cardiovascular and endocrine pharmacology and toxicology.
Reports describing de novo results of clinical studies and those that predominately or exclusively concern database mining and analysis and computational methodologies, e.g. CAMD, are outside the scope of the journal.Types of papers
(1) Full-length Research Papers. Biochemical Pharmacology publishes original research on issues of relevance to the field of pharmacology.
(2) Reviews and Commentaries. These articles are by invitation only and provide the authors' views on a selected topic of interest to pharmacologists.
Manuscript preparation and submission
Provided below is detailed information on the scientific criteria and manuscript formatting required for an article to be considered for publication in Biochemical Pharmacology. The online submission process includes the Scientific Checklist (Table 1). Failure to complete the Checklist, or a lack of a response to any items on the Scientific Checklist, automatically disqualifies the work for consideration. Note especially items 1 - 4 as a negative response to any of these automatically disqualifies the report for consideration. See Mullane et al., Guidelines for Manuscript Submission in the Peer-Reviewed Pharmacological Literature (Biochem. Pharmacol. 97:225-235, 2015; http://www.sciencedirect.com/science/article/pii/S0006295215003585) for a detailed discussion of the issues addressed in the Scientific Checklist.
Table 1. Scientific Submission Checklist
Please answer the following questions with "Yes", "No", or "Not applicable".
1. As Biochemical Pharmacology does NOT publish supplemental data with the exception of audio or video files, are all necessary data included in the body of the manuscript?
2. Are all tables and figures numbered and appropriately titled with descriptive legends that permit stand-alone interpretation?
3. Are all data shown in the figures and tables also shown in the text of the Results section and discussed in the Conclusions?
4. Does the e-mail address for the corresponding author indicate an affiliation with a research-based institution or has the author provided a separate statement written in English on institutional letterhead and signed by an official responsible for research activities for the institute verifying the affiliation listed by the corresponding author, along with the official's institutional e-mail contact information?
5. Is there a clear statement with background describing the hypothesis being tested by this study?
6. Are the primary endpoints clearly described?
Materials and Methods
7. The sources of all study materials are clearly indicated and is it acknowledged that reports containing experiments conducted with chemical mixtures, plant or animal extracts are not considered for publication unless the chemical structures and precise concentrations of all substances are reported?
8. Is (are) the chemical structure(s) of any new compound(s) presented as a figure in the manuscript or referenced in the peer-reviewed literature?
9. Are the source(s) and passage number of cell lines indicated?
10. Were cell lines authenticated by you or the vendor?
11. If used, has the selectivity of antibodies and/or interference RNA been validated and is/are their source clearly indicated?
12. If used, has the species, strain, sex, weight and source of the animals been provided?
13. Is a statement included in the text indicating compliance with regulations on the ethical treatment of animals including the identification of the institutional committee that approved the experiments?
14. Is the rationale provided for the selection of concentrations, doses, route and frequency of compound administration?
15. Are quantified results (e.g., IC50 and/or EC50 values) of concentration- and dose-response experiments included in the manuscript?
16. If used, is the method of anesthesia described?
17. Are all group sizes approximately the same?
18. Were the criteria used for excluding any data from analysis determined prospectively and clearly stated?
19. Was the investigator responsible for data analysis blinded to which samples/animals represent control and treatment groups?
20. Is the exact sample size (n) for each experimental group/condition clearly indicated in the text and/or in the tables and figures?
21. Are the reported data displayed as the mean +/- standard deviation (SD) of three or more independent experimental replications?
22. Is the number of replicates used to generate an individual data point in each of the independent experiments clearly indicated and is it equal to or greater than 3?
23. Were the statistical tests used to analyze the primary endpoints predetermined as part of the experimental design?
24. Is the threshold for statistical significance (P value) clearly indicated?
25. Were the data normalized?
26. Were post-hoc tests used to assess the statistical significance among means?
27. Were human tissues or fluids used in this study?
28. If western blots are shown, are the following included: i)appropriate loading controls for each western blot, ii)replication data, iii) quantification, and iv) the results of a statistical analysis?
29. If PCR and RT-PCR are included, were MIQE guidelines followed?
30. Was a reference standard (positive or negative controls) included in the study to validate the experiment?
31. Are all the findings considered within the context of the hypothesis presented in the Introduction
32. Are the primary conclusions and their implications clearly stated?
33. Are any secondary endpoints reported and are these sufficiently powered for appropriate statistical analysis?
34. Are the limitations of the current study or alternative interpretations of the findings clearly stated?
35. Indicate by checking the box at right that a conflict of interest statement is included in the manuscript
36. Indicate by checking the box at right that all organizations providing funding for this work are listed in Acknowledgements. Declaration of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck.
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
This journal offers authors a choice in publishing their research:
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.
• Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
• No open access publication fee payable by authors.
For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:Creative Commons Attribution (CC BY)
Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.
The open access publication fee for this journal is USD 3800, excluding taxes. Learn more about Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
All articles must be in editable files (e.g. Word, LaTeX) and submitted online at http://ees.elsevier.com/bcp. Articles submitted as pdfs will not be processed.
Authors must indicate on the title page which of the following categories best describes their work:
•Antibiotics and Chemotherapeutics
•Inflammation and Immunopharmacology
•Metabolic Disorders and Endocrinology
•Pharmacokinetics and Drug Metabolism
•Pulmonary, Renal and Hepatic Pharmacology
Neither the Editorial Board nor the reviewers will provide detailed advice for improving the grammar and clarity of a manuscript, regardless of the scientific merit of the work. Authors are responsible for ensuring the article is written in clear English. Either American or British usage is accepted, but not a combination of the two. Manuscripts lacking linguistic clarity or that are not prepared according to the style guidelines outlined below will not be considered for publication. Authors can have their manuscript language-edited. See English Editing Services under Useful Links below.
See http://www.elsevier.com/__data/assets/pdf_file/0003/91173/Brochure_UPP_April2015.pdf for specific instructions about recommended programs for manuscript preparation, including directions about the placement of mathematical equations, tables and figures and the use of spell-check and grammar-check.
Reports must be written in English with the pages numbered sequentially. The text must be double-spaced in single-column format with 1" or 25 mm margins. Size 12 (point) Times Roman or Arial font is preferred. The article must be divided into clearly defined sections. The required sections are Introduction, Materials and Methods, Results, Discussion, and References. See Mullane et al., Guidelines for Manuscript Submission in the Peer-Reviewed Pharmacological Literature (Biochem. Pharmacol.97:225-235, 2015; http://www.sciencedirect.com/science/article/pii/S0006295215003585) for a detailed discussion of the topics that must be covered in each section. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, …), 1.2, etc. The abstract is not included in section numbering. This numbering should be used for internal cross-referencing in the text. Subsections may be assigned a brief heading that appears alone on a separate line.
The article title should be concise but informative. All abbreviations must be spelled out fully when first mentioned in the abstract or body of the report.
Immediately following the abstract the authors must provide up to 6 keywords for indexing purposes. American spelling must be used, avoiding general and plural terms and multiple concepts. Only established abbreviations may be proposed as keywords.
You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the PubChem CID of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below:
Chemical compounds studied in this article
Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)
A list of all compounds cited in in the article must be provided immediately below the Keywords. This list will be used to extract relevant information from the NCBI PubChem Compound database for display in ScienceDirect next to the online version of the article. Authors may include up to 10 names of compounds mentioned in the article. For each compound the author must provide the PubChem CID of the most relevant record. For example, Glutamic acid (PubChem CID:611). PubChem CIDs can be found through http://www.ncbi.nlm.nih.gov/pccompound. The authors must follow the exact text formatting as in the example below:
Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)
More information on the compound database is available at http://www.elsevier.com/PubChem.
Acknowledgments must be listed in a separate section at the end of the article before the references. The Acknowledgments should include the names of individuals, organizations and funding agencies that provided assistance in underwriting and reporting the work.
Nomenclature and abbreviations
Receptor and ion channel nomenclature must conform to guidelines of the Committee on Receptor Nomenclature and Drug Classification of the International Union of Basic and Clinical Pharmacology (IUPHAR) (http://www.guidetopharmacology.org/nomenclature.jsp). Use only abbreviations that are generally accepted by the scientific community. Click HERE to view the full list of abbreviations that can be employed without definition. Drugs or other compounds should only be identified by their chemical or generic names. The source, including company name and location, for all chemicals, reagents, cell lines, tissue, and experimental animals must be provided in Materials and Methods.
GenBank accession numbers should be typed in bold, underlined text. Letters in the accession number should always be capitalized. Example: “…a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)…” In the final electronic version of the article, the accession number text will be linked to the appropriate source in the NCBI databases.
Footnotes should be used sparingly and numbered consecutively throughout the text. Indicate the position of footnotes in the text and list them separately at the end of the article. Do not include footnotes in the Reference list.
Illustrations must have a caption that is listed separately from the figure in the submitted version of the work. The caption should be self-explanatory without the need to reference the accompanying text. All symbols appearing on the illustration must be clearly defined in the figure legend.
All tables must be numbered consecutively in Arabic numerals and cited in the text in their order of appearance. Table titles should be brief and descriptive. Tables should appear individually on separate pages in the submitted version of the work, together with a legend that includes sufficient information about the experimental protocol and results so the reader does not have to refer back to the text to understand the experimental protocol and findings. Tables should not have vertical lines, and the number of horizontal lines should be minimized.
Citations in text
Ensure that every reference cited in the text is present in the reference list, and vice versa. Unpublished results and personal communications should not appear in the reference list, but may be indicated in the text.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.
[dataset]  M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1, 2015. http://dx.doi.org/10.17632/xwj98nb39r.1.
There are no strict requirements on reference formatting for the initial submission. References can be in any style or format as long as they are consistent within the manuscript. Regardless of the format, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be shown. Use of DOI is encouraged.
Most Elsevier journals have a standard template available in key reference management packages. This covers packages using the Citation Style Language, such as Mendeley (http://www.mendeley.com/features/reference-manager/: Elsevier [Numeric, with titles]) and also others like EndNote (http://endnote.com/downloads/style/biochemical-pharmacology) and Reference Manager (http://refman.com/downloads/styles/).
Institutional Email Address
As of January 1st, 2016 manuscripts will not be considered for publication in Biochemical Pharmacology if the email address for the corresponding author does not reflect an affiliation with a research-based institution. Alternatively, the submission must include a separate statement in English on institutional letterhead signed by an official responsible for research activities for the institute from which the manuscript originates verifying the affiliation listed by the corresponding author, along with the official's institutional email contact information.
Authors asked to submit a revised version of the work for consideration must also supply a graphical abstract at that time. The graphical abstract, which will be displayed on the online Table of Contents, should provide a concise summary of the work in pictorial form designed to capture the attention of a wide audience and for compilation of databases. Graphical Abstract text should not exceed 30 words. The content of the graphical abstract should be kept within an area of 5 cm tall by 17 cm wide (landscape shape). Authors are encouraged to limit graphical abstracts to 189 pixels tall by 642 pixels wide to ensure the image and text will be legible when displayed online. Authors must supply the graphic separately as an electronic file. See http://www.sciencedirect.com/science/journal/00062952/94/2 for examples of graphical abstracts.
Archival Material Requirement
At the manuscript revision stage all authors must submit, together with the revised manuscript, a zip-file titled "Archival_material.zip" that contains the original, uncropped and unedited photographs of all figures in the final article that represent gels, western blots, microscopic photos, etc. Failure to provide such original photographs will delay, or even preclude, publication in Biochemical Pharmacology.
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that give them a better understanding of the research described.
There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper. Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.
Listed below are links to sites that provide additional details on topics relating to the preparation and submission of manuscripts for publication in Biochemical Pharmacology as well as post-publication resources. English Editing Services: http://webshop.elsevier.com/languageediting
Electronic Artwork: https://www.elsevier.com/authors/author-schemas/artwork-and-media-instructions
Reference Formatting: http://endnote.com/downloads/style/biochemical-pharmacology
Acceptable Abbreviations: http://www.elsevier.com/__data/promis_misc/bcp_abbreviations.pdf
Audio/Video Files: http://www.elsevier.com/artworkinstructions; http://www.elsevier.com/audioslides
Database Linking: http://www.elsevier.com/databaselinking
Tracking Accepted Articles: http://www.elsevier.com/trackpaper.html
Commercial Reprints: https://www.elsevier.com/advertisers/our-services/commercial-reprints